AMP - Case Series of 103 Children with SARS-CoV-2 Infection in Portugal

AMP - Case Series of 103 Children with SARS-CoV-2 Infection in Portugal

Acta Médica PortuguesaThe North Lisbon University Hospital Center was activated for referral of SARS-CoV-2 infected patients on the 11th March 2020. The aim of this study is to describe the experience at the Department of Pediatrics in the...
BMJ - Risk stratification of patients admitted to hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: development and validation of the 4C Mortality Score

BMJ - Risk stratification of patients admitted to hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: development and validation of the 4C Mortality Score

British Medical JournalInternational Severe Acute Respiratory and emerging Infections Consortium (ISARIC) World Health Organization (WHO) Clinical Characterisation Protocol UK (CCP-UK) study (performed by the ISARIC Coronavirus Clinical...
JAMA - COVID-19 and the Path to Immunity

JAMA - COVID-19 and the Path to Immunity

JAMA NETWORKThe emergence of adaptive immunity in response to the novel Betacoronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), occurs within the first 7 to 10 days of infection. Understanding the key features and...
JAMA - Reassuring the Public and Clinical Community About the Scientific Review and Approval of a COVID-19 Vaccine

JAMA - Reassuring the Public and Clinical Community About the Scientific Review and Approval of a COVID-19 Vaccine

JAMA NETWORKPublic perception of the review of medications and vaccines for coronavirus disease 2019 (COVID-19) has become enmeshed in politics. The pressure on the US Food and Drug Administration (FDA) and Commissioner Stephen Hahn, MD, to...
WHO - Considerations for school-related public health measures in the context of COVID-19

WHO - Considerations for school-related public health measures in the context of COVID-19

World Health OrganizationCountries around the world are taking broad public health and social measures (PHSM), including closure of schools, to prevent the spread of the SARS-CoV-2 virus, which causes COVID-19.1 This Annex examines considerations...
WHO - Antigen-detection in the diagnosis of SARS-CoV-2 infection using rapid immunoassays

WHO - Antigen-detection in the diagnosis of SARS-CoV-2 infection using rapid immunoassays

World Health OrganizationA new technology for COVID-19 detection has become available that is much simpler and faster to perform that currently-recommended nucleic acid amplification tests (NAAT), like PCR. This method relies on direct detection...
AMP - SARS-CoV-2 Pandemic: Should Children Wear Masks?

AMP - SARS-CoV-2 Pandemic: Should Children Wear Masks?

Acta Médica Portuguesa

Carta o editor aborda a especificidade dos diferentes tipos de máscaras.

The Lancet - Azithromycin in addition to standard of care versus standard of care alone in the treatment of patients admitted to the hospital with severe COVID-19 in Brazil (COALITION II): a randomise

The Lancet - Azithromycin in addition to standard of care versus standard of care alone in the treatment of patients admitted to the hospital with severe COVID-19 in Brazil (COALITION II): a randomise

The LancetThe efficacy and safety of azithromycin in the treatment of COVID-19 remain uncertain. We assessed whether adding azithromycin to standard of care, which included hydroxychloroquine, would improve clinical outcomes of patients admitted...
The Lancet - Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia

The Lancet - Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia

The LancetWe developed a heterologous COVID-19 vaccine consisting of two components, a recombinant adenovirus type 26 (rAd26) vector and a recombinant adenovirus type 5 (rAd5) vector, both carrying the gene for severe acute respiratory syndrome...
JAMA - Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19 - A Meta-analysis

JAMA - Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19 - A Meta-analysis

JAMA NETWORK

Is administration of systemic corticosteroids associated with reduced 28-day mortality in critically ill patients with coronavirus disease 2019 (COVID-19)?

JAMA - Effect of Hydrocortisone on Mortality and Organ Support in Patients With Severe COVID-19 - The REMAP-CAP COVID-19 Corticosteroid Domain Randomized Clinical Trial

JAMA - Effect of Hydrocortisone on Mortality and Organ Support in Patients With Severe COVID-19 - The REMAP-CAP COVID-19 Corticosteroid Domain Randomized Clinical Trial

JAMA NETWORKDoes intravenous hydrocortisone, administered either as a 7-day fixed-dose course or restricted to when shock is clinically evident, improve 21-day organ support–free days (a composite end point of in-hospital mortality and the...
JAMA - Effect of Dexamethasone on Days Alive and Ventilator-Free in Patients With Moderate or Severe Acute Respiratory Distress Syndrome and COVID-19 The CoDEX Randomized Clinical Trial

JAMA - Effect of Dexamethasone on Days Alive and Ventilator-Free in Patients With Moderate or Severe Acute Respiratory Distress Syndrome and COVID-19 The CoDEX Randomized Clinical Trial

JAMA NETWORKIn patients with coronavirus disease 2019 (COVID-19) and moderate or severe acute respiratory distress syndrome (ARDS), does intravenous dexamethasone plus standard care compared with standard care alone increase the number of days...
JAMA - Effect of Hydrocortisone on 21-Day Mortality or Respiratory Support Among Critically Ill Patients With COVID-19 A Randomized Clinical Trial

JAMA - Effect of Hydrocortisone on 21-Day Mortality or Respiratory Support Among Critically Ill Patients With COVID-19 A Randomized Clinical Trial

JAMA NETWORK

Does low-dose hydrocortisone decrease treatment failure in patients with COVID-19–related acute respiratory failure?

NEJM - Phase 1–2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine

NEJM - Phase 1–2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine

The New England Journal of MedicineNVX-CoV2373 is a recombinant severe acute respiratory syndrome coronavirus 2 (rSARS-CoV-2) nanoparticle vaccine composed of trimeric full-length SARS-CoV-2 spike glycoproteins and Matrix-M1 adjuvant.
AMP - SARS-CoV-2 Pandemic: Should Children Wear Masks?

AMP - SARS-CoV-2 Pandemic: Should Children Wear Masks?

Acta Médica PortuguesaDuring the current SARS-CoV-2 pandemic, the World Health Organization has advised the use of masks, not only in healthcare facilities, but also in particular settings in the community where maintaining physical distance may...
Primeiro45679111213Último
Categorias

Categorias

Arquivo de Notícias

Arquivo